What we do Aarti Pharmalabs Limited manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and Xanthine derivatives, specializing in highly potent APIs for therapeutic segments like oncology and asthma. |
Founded in 2,019 |
Market share Leading Indian manufacturer of Xanthine derivatives with 15-20% global market share; strong presence in APIs and CDMO segments. |
Problem solved Provides high-quality, compliant APIs and intermediates critical for essential therapies, addressing global demand for reliable, regulated pharmaceutical ingredients. |
Top clients or who we serve Global pharmaceutical companies in generic and innovator markets across regulated and non-regulated regions; B2B focus with 500+ clients in 50+ countries. |
Key management - |
Our journey and innovations Started in 2001 with first API unit; expanded into regulated markets, secured multiple USFDA/EU approvals; demerged to focus solely on pharma in 2022; operationalized greenfield sites and expanded capacities. |
Where we operate Manufacturing and R&D in India (Maharashtra, Gujarat); exports to USA, Europe, Latin America, and 50+ countries worldwide. |
Top products or what we offer APIs including HPAPIs for oncology and chronic diseases, Xanthine derivatives like caffeine, and CDMO/CMO services with advanced process development. |
Top brands N/A as a B2B pharmaceutical ingredients supplier with flagship API and Xanthine product lines; recognized for quality and regulatory compliance. |
Raw materials needed Chemical raw materials for organic synthesis, catalysts, solvents, and intermediates for various API manufacturing processes. |
Raw materials supplier Not specified; sourced globally with focus on backward integration to reduce dependency. |
Recurring vs cyclical contribution Revenue predominantly recurring through long-term contracts with pharmaceutical clients alongside cyclical project-based CDMO services. |
Our industry position Market leader in Indian Xanthine derivatives; reputable CDMO/CMO player in regulated markets with strong regulatory certifications. |
Financial highlights FY25 consolidated revenue: INR 2,115 crore; PAT: INR 272 crore; EBITDA margin ~22%; consistent revenue and profit growth over recent years. |
Geographical revenue split 53% international sales, 47% domestic Indian sales as of FY26 nine months data. |
Order book Details not specified; ongoing expansion projects indicate robust demand and order pipeline. |
Whats driving growth Capacity expansions, regulatory approvals, China+1 supply shift, expanding CDMO footprint, renewable energy initiatives, and strong R&D pipeline. |
Our future plans Expand Xanthine capacity to 9,000+ MTPA; commission Atali greenfield intermediates and CDMO unit; increase global CDMO presence; enhance renewable energy use. |
Our green promise Invested in solar power, bio-briquette boilers, and Zero Liquid Discharge plants aiming for low carbon footprint and sustainable operations. |
Our people and values 2,300+ employees; focus on talent development, low attrition (11%), inclusive and engaged work culture with continuous learning opportunities. |
Key challenges ahead Operational ramp-up at new sites, margin pressure in API segment, continuous regulatory compliance, and competitive global pharmaceutical market. |
Interesting facts Largest Indian manufacturer of Xanthine derivatives; certified by USFDA, EU GMP, EDQM; extensive R&D with 62 patents filed; operates 7 manufacturing units. |
Risks and strategy Risks include market fluctuations, regulatory changes, and operational challenges; mitigated by diversification, compliance rigor, capacity expansion, and sustainability focus. |
